Bacopa monnieri vs PE-22-28
Side-by-side comparison of Bacopa monnieri and PE-22-28: mechanism, half-life, dose range, safety profile, and vendor pricing.
Price snapshot
Bacopa monnieri
PE-22-28
Bacopa monnieri
Bacopa monnieri is a creeping, succulent-leaved aquatic perennial that grows in wetlands, bogs, and rice paddies across the Indian subcontinent, Southeast Asia, northern Australia, and the southern United States. Known…
No vendor price on file.
Full Bacopa monnieri profilePE-22-28
PE-22-28 is a synthetic seven-amino-acid peptide (sequence PAGASRLLLLTGEIDLP derivative, commonly truncated to PE-22-28 as shorthand for "position 22-28" within the parent humanin-family sequence) that was designed as an…
Lowest listed price: $54.99 across 1 listing
Full PE-22-28 profileSide-by-side comparison
| Attribute | Bacopa monnieri | PE-22-28 |
|---|---|---|
| Category | Nootropic Adaptogen | Nootropics |
| Research Stage | Preclinical | Preclinical |
| Mechanism of Action | Bacopa monnieri's cognitive effects emerge from at least six convergent molecular mechanisms that span neurotransmitter modulation, trophic-factor expression, structural plasticity, antioxidant defense, vascular regulation, and receptor-level anxiolysis. No… | PE-22-28 is a synthetic 7-amino-acid peptide (sequence GVSWGLR) and a shortened analog of spadin. Its proposed mechanism is inhibition of the TREK-1 (TWIK-related K+) channel, a two-pore-domain potassium channel (K2P2.1 / KCNK2) implicated in mood regulation.… |
| Half-Life | — | Not characterized in humans. As a small 7-amino-acid peptide a short plasma half-life is expected; in mice the parent peptide spadin lost antidepressant activity by about 7 hours after a single dose, while modified analogs (e.g., G/A-PE 22-28) extended the behavioral effect to roughly 21-23 hours [PMID:28955242]. |
| Typical Dose Range | — | 250-2000 mcg subcutaneous per dose (empirical research-chemical community range; no clinically validated human dose exists; effective preclinical rodent doses were far lower, ~3 mcg/kg). |
| Dosing Frequency | — | Once daily or every other day (research-chemical community protocols; no validated clinical dosing schedule). |
| Administration | — | — |
| Side Effects | Bacopa monnieri's side-effect profile is dominated by gastrointestinal symptoms, which occur in 20-30% of users at therapeutic doses and represent the primary reason users discontinue the compound. Mechanistically, the GI effects appear to reflect Bacopa's… | No human side-effect data exist for PE-22-28 because it has never been tested in people. What can be said comes from rodent studies of PE-22-28, spadin and their analogs, plus general considerations for injected research peptides. In the preclinical work, the… |
| Molecular Weight | — | 773.9 g/mol |
| Common Vial Sizes | — | — |
Price tracking
Bacopa monnieri: potential benefits
- No structured benefit list published.
PE-22-28: potential benefits
- Antidepressant-like effects in rodent models of depression (preclinical only)
- Potent, selective inhibition of the TREK-1 (K2P2.1) potassium channel (IC50 ~0.12 nM)
- Rapid-onset (~4-day) antidepressant profile in animals, unlike the multi-week lag of SSRIs
- Increased hippocampal neurogenesis in mice
- Increased cortical synaptogenesis (PSD-95) and BDNF expression in preclinical studies
- No human-validated benefits; not approved for any use (research use only)
Frequently asked
What's the difference between Bacopa monnieri and PE-22-28?
Bacopa monnieri is a nootropic adaptogen that bacopa monnieri's cognitive effects emerge from at least six convergent molecular mechanisms that span neurotransmitter modulation, trophic-factor expression, structural…. PE-22-28 is a nootropics that pe-22-28 is a synthetic 7-amino-acid peptide (sequence gvswglr) and a shortened analog of spadin. its proposed mechanism is inhibition of the trek-1 (twik-related k+) channel, a…. The two differ in mechanism, half-life (not reported vs Not characterized in humans. As a small 7-amino-acid peptide a short plasma half-life is expected; in mice the parent peptide spadin lost antidepressant activity by about 7 hours after a single dose, while modified analogs (e.g., G/A-PE 22-28) extended the behavioral effect to roughly 21-23 hours [PMID:28955242].), and typical dose range.
Which has the longer half-life, Bacopa monnieri or PE-22-28?
Bacopa monnieri has a half-life of not reported. PE-22-28 has a half-life of Not characterized in humans. As a small 7-amino-acid peptide a short plasma half-life is expected; in mice the parent peptide spadin lost antidepressant activity by about 7 hours after a single dose, while modified analogs (e.g., G/A-PE 22-28) extended the behavioral effect to roughly 21-23 hours [PMID:28955242].. Longer half-lives generally mean less frequent dosing but slower on/off kinetics.
Can you stack Bacopa monnieri and PE-22-28?
Stacking depends on mechanism overlap, safety profile, and goals. Bacopa monnieri and PE-22-28 should only be stacked after reviewing each compound's individual protocol page, side effect profile, and any published interaction data. Use the BodyHackGuide stack builder for a structured review before combining research compounds.
See current vendor prices
Listings from the vendors we track. Prices change often, so check the vendor before you buy.
Before you buy Bacopa monnieri or PE-22-28
Check the vendor trust score. Every supplier we track is rated 0-100 on COA verification, payment transparency, shipping, reviews, and listings: one published, reproducible methodology, applied to every vendor.
Related comparisons
Research use only. BodyHackGuide is a research and price-comparison reference. The compounds discussed on this page are not approved by the FDA for human consumption and are sold strictly for laboratory research. Prices shown are pulled from vendor listings tracked on BHG and are subject to change. Every vendor is ranked on the same public, reproducible methodology. See editorial standards and affiliate disclosure.